IRIS-associated Kaposi sarcoma management — the paradoxical KS flare following HIV antiretroviral therapy initiation requiring immunomodulatory intervention alongside continued viral suppression — represents the fastest-growing clinical challenge segment in the Kaposi sarcoma market, with the Kaposi Sarcoma Market reflecting IRIS-directed therapy as the HIV-KS integrated care...